Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
Holding WVE?
Track your performance easily
WVE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.50 - $16.74
Previous Close$12.85
Volume1.34M
Average Volume (3M)1.79M
Market Cap
$2.17B
Enterprise Value$1.80B
Total Cash (Recent Filing)$310.90M
Total Debt (Recent Filing)$27.17M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Feb 27, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding152,519,770
10 Day Avg. Volume1,506,224
30 Day Avg. Volume1,791,551
Standard Deviation0.30
R-Squared0.04
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)15.28
Price to Sales (P/S)34.02
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.39
Enterprise Value/Gross Profit15.90
Enterprise Value/Ebitda-13.22
Forecast
1Y Price Target
$22.56Price Target Upside58.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Wave Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe decline in mutant HTT biomarker by 46% in SELECT-HD trial supports the potential efficacy of Wave Life Sciences' therapeutic approach for Huntington's disease.
Financial PerformanceAnalyst recommends a buy rating for Wave Life Sciences with a price target of $22, indicating confidence in the company's future prospects.
Regulatory ApprovalThe FDA is supportive of a potential path to accelerated approval for WVE-003 in Huntington's disease, which would involve a registrational Ph2/3 study using biomarkers as study endpoints.
Bears Say
Clinical TrialsDecision to advance WVE-003's HD program into Ph2/3 is putting some pressure on shares due to uncertainties around caudate imaging as an approvable surrogate biomarker and potential costs.
Investor SentimentExpectations on the program are low—the majority of investors seem to be focused on the AATD and INHBE programs, with the few inbounds on DMD leaning bearish.
Market PerceptionLimited value priced in for DMD program at current levels, with the majority of investors focused on other programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $3.50 and its highest was $16.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Currently, no data Available
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Feb 27, 2025 which is in 98 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Nov 12, 2024. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.187.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -$0.19.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 152,519,780 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went down -3.345%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Among the largest hedge funds holding Wave Life Sciences’s share is RA Capital Management. It holds Wave Life Sciences’s shares valued at 149M.
---
Wave Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.56 (58.76% Upside)
$22.56 (58.76% Upside)
Blogger Sentiment
Bullish
WVE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 159.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $22.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.89%
12-Months-Change
Fundamentals
Return on Equity
-243.82%
Trailing 12-Months
Asset Growth
79.33%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
---
WVE Earnings Call
Q3 2024
0:00 / 0:00
---
WVE Stock 12 Month Forecast
Average Price Target
$22.56
▲(58.76% Upside)
Technical Analysis
Arcturus Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering WVE
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+91.35%
reiterated a buy rating 9 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +91.35% per trade.
---